









Markets
/
Stocks
/
nasdaq-tgtx
/

TG Therapeutics Inc

TGTX

32.370USD

-0.240-0.74%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

5.12BMarket Cap

84.61P/E TTM



TG Therapeutics Inc

32.370

-0.240-0.74%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

26 / 175

Overall Ranking

110 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 9 analysts

Buy

Current Rating

42.333

Target Price

+29.82%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 11713.43% year-on-year.

Overvalued

The company’s latest PE is 78.22, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 115.94M shares, decreasing 15.68% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 15.77M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of -0.19.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 8.26, which is higher than the Pharmaceuticals industry's average of 7.84. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 141.15M, representing a year-over-year increase of 92.13%, while its net profit experienced a year-over-year increase of 309.75%.

Score

Industry at a Glance

Previous score

8.26

Change



Financials

6.36

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.28

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.69

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 3.58, which is higher than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is 78.80, which is -11.48% below the recent high of 69.75 and 114.67% above the recent low of -11.56.

Score

Industry at a Glance

Previous score

3.58

Change

0.03

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 26/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 7.56, which is lower than the Pharmaceuticals industry's average of 7.78. The average price target for TG Therapeutics Inc is 48.00, with a high of 55.00 and a low of 11.00.

Score

Industry at a Glance

Previous score

7.56

Change

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts

Buy

Current Rating

42.333

Target Price

+29.82%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

TG Therapeutics Inc

TGTX

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 9.24, which is higher than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 34.70 and the support level at 29.21, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.24

Change

-0.12

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.523

Buy

RSI(14)

57.945

Neutral

STOCH(KDJ)(9,3,3)

56.863

Neutral

ATR(14)

1.212

High Vlolatility

CCI(14)

122.189

Buy

Williams %R

23.624

Buy

TRIX(12,20)

0.337

Sell

StochRSI(14)

59.872

Neutral

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

32.152

Buy

MA10

32.158

Buy

MA20

31.012

Buy

MA50

32.069

Buy

MA100

34.396

Sell

MA200

34.345

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 73.03%, representing a quarter-over-quarter decrease of 1.04%. The largest institutional shareholder is The Vanguard, holding a total of 15.77M shares, representing 9.94% of shares outstanding, with 0.56% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

19.22M

-2.36%

The Vanguard Group, Inc.

Star Investors

15.57M

+0.05%

Weiss (Michael S)

13.82M

State Street Global Advisors (US)

7.43M

-19.20%

Geode Capital Management, L.L.C.

3.28M

+2.79%

ClearBridge Investments, LLC

2.64M

+44.10%

Soleus Capital Management, L.P.

2.85M

+6.17%

Pictet Asset Management Ltd.

2.40M

-14.20%

Hood River Capital Management LLC

1.56M

+6.95%

Fidelity Management & Research Company LLC

1.74M

+68.88%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 4.07, which is equal to the Pharmaceuticals industry's average of 4.07. The company's beta value is 1.94. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.